Juniper Pharmaceuticals, Inc.
We are investigating the sale of Juniper Pharmaceuticals, Inc. (“Juniper” or the “Company”) (JNP) to Catalent Inc. (CTLT) (“Catalent”). Under the terms of the transaction, Juniper shareholders will receive $11.50 for each share of Juniper common stock that they own.